Deals
J&J Reaches $2.1 Billion Deal to Sell Diabetes Device Business
This article is for subscribers only.
Johnson & Johnson got a $2.1 billion offer from a private-equity firm for its glucose monitor business LifeScan, the drugmaker said Friday.
The company said in January of last year that it was considering options for the diabetes device business as part of a broader effort to focus on its core health-care offerings. The deal, with Platinum Equity, is expected to close by the end of the year.